TuHURA Biosciences, Inc. (HURA)
| Market Cap | 134.46M -7.4% |
| Revenue (ttm) | n/a |
| Net Income | -30.63M |
| EPS | -0.54 |
| Shares Out | 63.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 99,650 |
| Open | 2.150 |
| Previous Close | 2.130 |
| Day's Range | 2.040 - 2.150 |
| 52-Week Range | 0.410 - 3.430 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 8.04 (+281.04%) |
| Earnings Date | Aug 14, 2026 |
About HURA
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for HURA stock is "Buy." The 12-month stock price target is $8.04, which is an increase of 281.04% from the latest price.
News
TuHURA Biosciences Transcript: AGM 2026
The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Earnings release: Q2 2026
TuHURA Biosciences released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
TuHURA Biosciences Quarterly report: Q2 2026
TuHURA Biosciences has published its Q2 2026 quarterly earnings report on August 14, 2026.
TuHURA Biosciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
The company is advancing a phase III trial for frontline Merkel cell carcinoma with FDA support, targeting accelerated approval and leveraging novel immunotherapy platforms. Additional programs include a VISTA-inhibiting antibody for AML and innovative ADCs, with key data and regulatory milestones expected within the next year.
TuHURA Biosciences Slides: Corporate presentation
TuHURA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences Proxy statement: Proxy filing
TuHURA Biosciences filed a proxy statement on June 26, 2026, providing details for shareholder voting and corporate governance matters.
TuHURA Biosciences files IND application with FDA for study of TBS-2025
TuHURA Biosciences (HURA) announced that it has filed an Investigational New Drug application with the U.S. FDA for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of…
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myel...
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Earnings release: Q1 2026
TuHURA Biosciences released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
TuHURA Biosciences Quarterly report: Q1 2026
TuHURA Biosciences has published its Q1 2026 quarterly earnings report on May 15, 2026.
TuHURA Biosciences Slides: Corporate presentation
TuHURA Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...
TuHURA Biosciences initiated with an Outperform at Citizens
Citizens initiated coverage of TuHURA Biosciences (HURA) with an Outperform rating and $9 price target TuHURA is a clinical-stage immuno-oncology company focused on novel mechanisms in cancer, the ana...
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones TAMPA, Fla., April 22, 2026 /PRNewswire/ -- T...
TuHURA Biosciences initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $7 price target The firm’s target is based on its estimate of the probability-adjusted sum-of-the-parts valuation...
TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company...
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to...
TuHURA Biosciences Earnings release: Q4 2025
TuHURA Biosciences released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
TuHURA Biosciences Annual report: Q4 2025
TuHURA Biosciences has published its Q4 2025 annual report on March 31, 2026.
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
Distinguished physician with a career spanning over 29 years in drug development and medical affairs highlighted by blockbuster successes in hematology and oncology Coordinated and achieved more than ...